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Angiogenesis, haemostasis and cancer:
new paradigms and old concerns
Angiogênese, homeostasia e câncer: novos paradigmas e velhos problemas
Maria Duarte1; Adhemar Longatto Filho1,2; Fernando C. Schmitt3
Neovascularization is a crucial phenomenon for the continuous growing of neoplastic cells and cancer 
progression. The growth of new blood vessels from pre-existing vessels (angiogenesis) occurs in several 
physiological and pathological conditions, including cancer, where it is critical for tumor-cells nutrition. 
Recently, new remarkable insights regarding angiogenesis and blood coagulation (key events in vascular 
biology) have been described. The serine protease thrombin, which plays a central role in blood coagulation 
cascade through its ability to cleave fibrinogen conducting to fibrin clot formation, is also known to be involved 
in embryogenesis, inflammation, wound healing, through its active role on vascular remodeling. Although 
the increased knowledge of factors regulating angiogenesis and coagulation led to the understanding that 
angiogenesis, homeostasis and carcinogenesis are three close team players, little is still known about how 
these pathways support each other in the process of angiogenesis in vivo. This review summarizes current 
understanding of blood coagulation cascade role in conducting angiogenesis and tumor progression, as well 




A neovascularização é um processo fundamental para a sobrevivência e a progressão das células 
neoplásicas malignas. O crescimento de novos vasos sanguíneos a partir de vasos já existentes, fenômeno 
designado como angiogênese, está envolvido em vários processos fisiológicos e patológicos, incluindo 
o crescimento tumoral, onde a angiogênese desempenha papel crítico na nutrição das células tumorais. 
Tal como a angiogênese, o sistema de coagulação sanguínea exerce importante função na biologia 
vascular. A trombina, uma serina protease, tem papel fundamental na cascata de coagulação, pela 
quebra enzimática do fibrinogênio e pela conseqüente produção de fibrina. Essa protease encontra-se 
também implicada em desenvolvimento embrionário, inflamação e cicatrização, processos nos quais a 
remodelação vascular está altamente ativa. Apesar de o crescente conhecimento de fatores reguladores 
da angiogênese e da coagulação demonstrar que a carcinogênese, a coagulação e a angiogênese são 
três close team players, ainda muito pouco se sabe sobre o modo como esses players comunicam-se e 
interagem no processo de angiogênese in vivo. Esta revisão sumariza os conhecimentos atuais quanto ao 
papel da cascata de coagulação na condução do processo angiogênico e do crescimento tumoral, bem 
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Introduction
During embryonic vasculogenesis, blood vessels 
are formed from endothelial cell (EC) precursors – 
angioblasts –, which assemble into a primary capillary 
plexus. This primitive network then differentiates, and 
new blood vessels sprout and branch from pre-existing 
capillaries during the process of angiogenesis, being 
stabilized by mural cells (pericytes in medium-sized 
and smooth muscle cells [SMC] in large vessels), which 
then regulate EC proliferation, survival, migration, 
differentiation, vascular branching, blood flow and 
vascular permeability(2, 4) (Figure 1).
Blood vessels run through virtually every organ in the 
body (except the avascular cornea and the cartilage), 
assuring metabolic homeostasis by supplying oxygen 
and nutrients and removing waste products. Therefore, 
angiogenesis is known to be essential in several physiologic 
processes, such as organ growth and development, wound 
healing and post-ischemic tissue repair(16, 52). Under these 
circumstances, angiogenesis occurs in a highly regulated 
manner whereby pro-angiogenic factors stimulate a phase 
of rapid migration, proliferation, followed by a phase of 
vessel differentiation and maturation of ECs. Eventually, 
the endothelium monolayer becomes quiescent and a local 
balance of pro- and anti-angiogenic factors tightly regulates 
the whole process. The moment in which this “normal” 
balance is disrupted mediates the “angiogenic switch”(20) 
towards pathological angiogenesis, in the course of 
process, such as tumor growth and metastasis, rheumatoid 
arthritis, diabetic retinopathy, and psoriasis(16, 45, 54, 68). This 
switch clearly involves more than simple upregulation of 
angiogenic activity and is known to be the result of net 
balance between positive and negative regulators.
There are three particularly important stimulators 
of angiogenesis: i) vascular endothelial growth factor 
(VEGF)(14, 53); ii) fibroblast growth factor (FGF)(33, 59); iii) 
angiopoetins (Ang)(9, 36); between many others, like platelet-
derived growth factor (PDGF), epidermal growth factor (EGF), 
ephrins(22); transforming growth factors alpha and beta (TGF-α 
and -β), interleukins, chemokines, and small molecules, such 
as sphingosine 1-phosphate(51), that are known to promote 
cell proliferation, survival and differentiation of ECs(56, 60). For 
a general overview of the different molecular players involved 
in the angiogenesis process, see Figure 1.
Vascular endothelial growth factor
Initially identified for its ability to mediate vascular 
permeability, VEGF was later found to be a mitogen 
agent for ECs(31, 58). Today VEGF is recognized as an 
essential cytokine for the development and homeostasis 
Figure 1 – Angiogenesis and homeostasis cycles. In response to an angiogenic stimulus, the endothelial cell contacts are disrupted, triggering the blood coagulation cascade, in 
which several proteases are activated. Thrombin-induced signaling in the endothelium results in multiple phenotypic changes, as well as expression and release of several different 
molecules, known to play a crucial role as angiogenic stimulators, contributing to cell migration and proliferation, cell alignment and tubule formation, and the maturation of vascular 
structures into vessels by investment with mural cells, which can either be pericytes, in the case of small vessels, or smooth muscle cells, in the case of larger ones. All these steps lead 
to the formation of a continuous lumen with flow. Factors which control the various steps are listed
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of cardiovascular systems. Inactivation of a single VEGF 
allele results in embryonic lethality at mid-gestation due to 
severe cardiovascular defects(5, 13). The biologic activities of 
VEGF are mediated principally by two related cell surface 
receptors, VEGFR1 and VEGFR2, with extracellular ligand-
binding domains and intracellular protein-tryrosine kinase 
domains(44). Although the role of VEGFR1 remains a little 
bit controversial, the activation of VEGFR2 has been shown 
to promote differentiation of progenitor’s cells, migration, 
mitogenesis, survival, nitric oxide release, and vascular 
permeability(26, 39, 70, 72, 74). While neonatal mice expression 
of VEGF is required for survival(18), the function of VEGF 
signaling in adult vessels is less clear. There is evidence 
that activation of this signaling pathway is required for the 
maintenance of fenestrations in certain vascular beds(11). 
Blockage of VEGF signaling in adult mice has resulted in 
reduced capillary density and proteinuria.
Fibroblast growth factor
The family of FGFs comprises 24 structurally related 
members, acting in concert with heparin sulphate proteoglycan 
to mediate a great variety of cellular responses through binding 
and activation of four receptor tyrosine kinase, the fibroblast 
growth factor receptors (FGFRs)(24). FGF1, the founding 
member of the FGF family, is able to influence each critical 
stage of angiogenesis, including EC detachment, migration, 
proliferation, and ultimate differentiation into a functional 
capillary vessel(50, 57). Within extracellular matrix degradation, 
FGF1 is involved in the upregulation of urokinase plasminogen 
activator (uPA) and matrix metalloproteases (MMPs), and 
expression modulation of uPA receptor on the EC surface, 
thus allowing the localization of the proteolytic activity at 
the leading edge of the cell at the front of migration(38). 
FGFRs are crucial patterns of FGF-induced angiogenesis, 
FGFR1 null embryos are developmentally retarded and dye 
during gastrulation(71), however expression of a dominant 
negative form results in a significant impairment of blood 
vessel development(30). It has recently been demonstrated 
that FGFR1 and FGFR2 carry distinct roles in regulating 
cell survival, thus while FGFR1 induced cell survival, FGFR2 
activation promoted cell apoptosis, suggesting that they may 
play distinct roles within the same cell context(69). Interestingly, 
an intimate crosstalk seems to exist between FGF2 and 
different members of the VEGF family during angiogenesis, 
lymphangiogenesis, and vasculogenesis, underlying the 
complexity of angiogenesis, a regulated mechanism, where 
each phase of the angiogenic cycle is highly regulated.
Angiopoetins: tie signaling axis
Ang1 belongs to a family of ligands currently comprising 
four members(9). From these, Ang1 and Ang2 are more 
understood with respect to their roles in developmental 
and pathological angiogenesis. Although these two ligands 
bind to the receptor tyrosine kinase Tie2 with similar 
affinities, Ang2 can inhibit Ang1 under some specific 
physiological contexts(36). In adult settings Ang1 is a natural 
anti-permeability factor, protecting against excessive 
plasma leakage, since it contributes to stabilization of pre-
existing vessels or maturation of newly formed ones by 
the recruitment of pericytes and SMCs(63). On the other 
hand, Ang2 can either be involved in the regression or the 
formation of new blood vessels, since this angiogenic factor 
has the capacity to block its receptor (Tie2), promoting 
either the regression or the sprouting of vessels, depending 
on VEGF presence. Thus Ang2 is preferentially expressed 
at angiogenic and vascular remodeling sites, enabling exit, 
migration and proliferation of EC, or its regression during 
the process of angiogenesis(36, 49).
Endogenous inhibitors of angiogenesis include hormone 
metabolites, and apoptosis modulators(16). Curiously, many 
inhibitor molecules, such as “statins”, are derived from 
larger proteins that have no effect on angiogenesis(46). 
Among those is angiostatin(48), a fragment of plasminogen 
that binds directly to adenosine triphosphate synthase on 
the surface of ECs, which might play a role in intracellular 
acidifications triggering apoptotic events in EC(41). Other 
anti-angiogenic proteins resulting from proteolysis of larger 
molecules are endostatin (a fragment of collagen XVIII)(47, 61), 
tumstatin(34), and canstatin (fragments of collagens that 
bind to integrins)(27). Some full-length extracellular proteins 
also display anti-angiogenic activity. Among them are 
thrombospondin-1, -2, and -3, produced by normal 
fibroblasts(19); interferon alpha, produced by leucocytes(55); 
and platelet factor 4(35).
The haemostatic system (or coagulation cascade), which 
coordinates the cessation of blood loss from damaged 
vessels, regulating platelets adherence and fibrin formation, 
is normally inactive in adults due to a balance between pro- 
and anti-coagulant proteins present in the blood stream. 
In recent years, it has become increasingly evident that the 
blood coagulation system represents a major regulatory tool 
in vascular development. Indeed, the EC surface, which is 
the area of contact between the fluid blood compartment 
and the vessel wall, is the site where coagulation cascade 
conducts its activity, especially when the endothelium 
is injured or denuded. Under these circumstances, the 
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permeability of the damaged vessel is augmented, resulting 
in the extravasation of fibrinogen and fibronectin and the 
formation of the fibrin clot that acts as temporary scaffold 
for migrating ECs. Resolution of venous thrombus involves 
the formation of vascular channels within the thrombus 
and new blood vessels, contributing to restoration of blood 
flow(67). These events result in migration of proliferating ECs 
into fibrin mesh in order to repair the vessel wall and in 
the further adhesion and spreading of ECs, leading to the 
understanding that angiogenesis and coagulation systems 
are closely interconnected (Figure 1).
Angiogenesis, haemostasis and 
carcinogenesis: how do they link?
Blood vessels neovascularisation not only allows for the 
continued growth of the primary tumor, but also provides 
migrating tumor cells access to the systemic circulation, 
facilitating metastisation. The involvement of vascular system 
in tumor growth obviously encompasses angiogenesis, 
and induces also systemic hypercoagulability and a pro-
thrombotic state. The haemostatic system, as already 
mentioned, is normally inactive in adults. The response to 
a vascular injury is considered to begin after disruption of 
the vessel wall and exposure of tissue factor (TF), which is 
involved in process of tumor growth, angiogenesis, and 
metastasis(32). Interestingly, certain genetic events directly 
associated to tumorigenesis, like expression of Kirsten rat 
sarcoma viral oncogene homolog (K-ras), epidermal growth 
factor receptor (EGFR), phosphatase and tensin homologue 
(PTEN) or p53 mutants, have been demonstrated to lead 
to an increase in TF levels, as well as its activity. Therefore, 
they promote tumor aggressiveness, angiogenesis, and 
hypercoagulability, originating thrombin in the surrounding 
environment, which will then lead to platelet activation, 
being accompanied by important physical, biological, 
and biochemical events. Procoagulant phospholipids 
(phosphatidylserine) are then exposed, as binding sites that 
allow assembly of coagulation proteins on the platelet’s 
outer leaflet, conducting to a burst of thrombin generation. 
The sustained generation of serine protease thrombin, for 
example, at sites of thrombosis, has focused attention on 
vascular remodeling in response to thrombosis, as well 
as other vascular injuries. This serine protease has also 
been shown to degrade various constituents of basement 
membranes, and thus may facilitate cell invasion and 
increase the metastatic potential of neoplastic cells. 
Experiments conducted by Tsopanoglou and Maragoudakis 
several years ago demonstrated that a brief exposure (less 
than 15 minutes) of ECs to thrombin causes a marked 
inhibition of their ability to adhere to type IV collagen and 
laminin, suggesting that thrombin enables ECs to detach 
from their anchorage site on the basement membrane 
of the neighboring vessel, to survive without attachment 
to the extracellular matrix and allowing their migration 
to distant sites(65). Complementary, the role of bone 
marrow (BM) cells in angiogenesis, vascular regeneration, 
tumor formation, and thrombus recanalization has been 
extensively documented(40), what requires mobilization 
of progenitor cells into circulation, recruitment at the 
target site, and further expression and differentiation into 
appropriate cell types. Tarzani et al. have demonstrated that 
thrombin promotes BM cells proliferation and endothelial 
cell progenitors differentiation into ECs(62), in a mechanism 
mediated by protease-activated receptor (PAR)1 activation, 
a major thrombin G-protein coupled receptor(66). These 
noteworthy findings may have important implications for 
the role of coagulation factors, particularly thrombin, in BM 
progenitor cell biology. Thus, in addition to modulating 
pre-existing vascular cells, thrombin may also impact repair 
mechanisms and angiogenesis by affecting BM-derived 
progenitor cells to proliferate and differentiate.
The premalignant role of thrombin in tumor adhesion, 
growth, metastasis, and angiogenesis is well recognized, and 
in general correlated with overexpression and activation of 
PAR1. There are emerging evidences that PAR1 modulates cell 
proliferation and motility in physiophathologic cell invasion 
process, suggesting its role in the setting of cancer growth and 
metastasis. Indeed, the involvement of PAR1, which can be 
activated by thrombin, in the invasive and metastatic processes 
is known for different tumors, like breast, melanoma, and colon 
cancer(8, 12, 15, 28). The molecular mechanisms underlying PAR1-
induced tumor invasion remain to be elucidated, and possible 
hypotheses, including the involvement of different players like 
growth factors and cytoskeleton-related proteins, which will 
promote cellular growth and cytoskeleton reorganisation, 
need urgently to be addressed.
Thrombin through PAR1 activation is known to modulate 
the expression of several mitogen factors, including PDGF, 
FGF2, and VEGF, well-known pro-angiogenic factors(1, 3, 6, 7). 
We recently found that thrombin, through PAR1 activation, 
is also able to induce the expression and the release of 
FGF1, a potent mitogen for different cell types, and a well-
known angiogenic factor(10), linking haemostasis to the 
neovascularisation process, most probably in both normal 
and abnormal context.
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Thus, several angiogenic players are shared and/or 
activated by haemostasis, conducting to the idea that 
during the process of tumor growth, angiogenesis as well 
as haemostasis processes can serve as “feeder” sources, 
allowing the growth and survival of tumor cells, and its 
further invasion, utilizing the newly formed vascular tree as 
a route for metastization at different organs (Figure 2).
Pro- and anti-angiogenesis 
treatment: from here to where?
During the last two decades, an explosive interest in 
angiogenesis research has generated the indispensable 
insights to develop the first clinically approved anti-
angiogenic agents for cancer and blindness. This novel 
treatment is likely to change the face of medicine in the next 
decade, as over 500 million people worldwide are estimated 
to benefit from pro- or anti-angiogenesis treatment.
The concept that angiogenesis is essential for tumor 
growth and metastasis, representing a necessary step in the 
control of cancer development, which could be regulated 
by pharmacological and/or genetic suppression of blood 
vessel growth, has engendered a long-standing interest in 
the identification of molecules or synthetic compounds that 
block angiogenesis(20). Anti-angiogenesis therapy has been 
appealing for cancer treatment for three major reasons: i) it 
is possible that most tumors are dependent on angiogenesis, 
thereby providing a common target in the treatment of 
widely heterogeneous disease; ii) ECs are considered to be 
less likely to develop adaptations to bypass drug effects; iii) 
it is anticipated that tumor vessels are proliferative, therefore 
providing a differential target than the quiescent vessels 
present in normal tissues.
In the context of either anti-angiogenesis (to block 
vessel growth) or pro-angiogenic (to enhance vessel 
growth) therapies, VEGF and VEGF receptors seem to be 
a case of experimental and clinical success. Bevacizumab 
(avastin)(17, 75), Bay 43-9006 (sorafenib), and SU 11248 
(sunitinib) are some of the antivascular agents in clinical 
development already approved by the United States Food 
and Drug Administration (FDA) for cancer treatment. 
Bevacizumab, a humanized monoclonal antibody against 
VEGF, when used with chemotherapy in metastatic 
colorectal cancer patients, demonstrated a prolonged overall 
survival(23). In subsequent phase III trials, bevacizumab in 
combination with standard chemotherapy improved overall 
survival in lung and progression-free survival in breast cancer 
patients(25). It has also been reported to be active in patients 
with metastatic renal-cell cancer as monotherapy(73). Further 
clinical success was recently obtained with broad-spectrum 
Figure 2 – The central actions of thrombin as mediator of blood coagulation cascade, angiogenesis and carcinogenesis. Thrombin is a multifunctional serine protease generated 
at a site of vascular injury, being the most effective agonist for platelet aggregation and activation. Thrombin also elicits a host of responses in the vascular endothelium, including 
shape and permeability changes, mobilization of adhesive molecules, and stimulation of different cytokines and growth factors, which when deregulated can promote the angiogenic 
switch leading to an exaggerated neovascularization, frequently detected in several tumours. Thrombin is also able to activate endothelial PAR1, which is known to be up-regulated 
in different tumours types. Therefore, all these evidences suggest that during the process of tumour growth, angiogenesis as well as haemostasis can serve as “feeder” sources for the 
tumour cells, underlying a close relationship among them
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multitargeted agents who target VEGF receptors and other 
tyrosine kinases present in endothelial and cancer cells. 
Phase III trials have demonstrated the efficacy of SU 11248 
(sunitinib [targeting VEGFR1, 2, PDGF receptor, and c-Kit]) 
and Bay 43-9006 (sorafenib [targeting VEGFR2, 3, PDGFR, 
RET, c-Kit and Raf]) in the treatment of patients with renal 
cancer(25). Based on these results sunitinib and sorafenib are 
now approved by the Food and Drug Administration (FDA) 
as monotherapies for kidney cancer. The clinical success of 
bevacizumab, sunitinib, and sorafenib as novel medicines 
for treatment of cancer patients has confirmed the relevance 
of angiogenesis research and has stimulated the search for 
novel and more effective anti-angiogenic approaches.
However, it is important to notice that some clinical 
trials designed to test anti-angiogenic therapy have met 
variable and rather disappointing success. In particular, 
not all tumor vessels appear equally susceptible to a 
single modality of anti-angiogenic therapy. There are 
many reasons for this type of response. For example, the 
participation of tumor cells in the vascular wall (“vascular 
mimicry”) has been demonstrated in uveal carcinoma, and 
more recently in melanoma(21). How responsive are these 
cells to anti-angiogenic therapy? The molecular nature 
of tumor microvessels appears to be more variable than 
anticipated, and differences in the tumor microenvironment 
are likely to influence therapeutic outcome. Although 
some antivascular agents have demonstrated activity as 
monotherapies, most human trials to date indicate that 
they are most effective when combined with conventional 
antitumor strategies(25, 29).
Anticoagulant therapy: would it 
mean less angiogenesis and a better 
tumor survival outcome?
In the nearly 135 years since Trousseau first described 
migratory thrombophlebit is in cancer patients, 
thromboembolism has become a well-established 
presenting sign and complication of cancer(64). Indeed, two 
large epidemiological studies involving 86,000 patients 
with thromboembolism, 4,200 of which had cancer, 
suggest that the risk of deep vein thrombosis or pulmonary 
thromboembolism is 3.2 times higher in cancer patients(37). 
On the other hand, the risk of thrombosis is increasing with 
anti-neoplastic treatment, most probably due to cytotoxic 
damages within the endothelium, which then releases 
procoagulant substances and cytokines, responsible 
for blood coagulation activation. As results of these 
findings, anti-thrombotic therapy is considered a rational 
approach to prevent thromboembolism in cancer patients. 
Interestingly, as we will discuss next, effective antithrombin 
therapy seems to reduce the risk of cancer progression 
and even prolongs overall survival. The coagulation 
system is activated in cancer and is further amplified 
by treatment with chemotherapy, radiation or surgery. 
Hypercoagulation is documented in virtually all cancer 
types, albeit at different rates, and is the second leading 
cause of death in cancer patients. The relationship between 
clotting activation and carcinogenesis supports the view of 
cancer as a hypercoagulable state and holds implications 
for the development of thrombosis, enhancement of tumor 
growth and risk of poor clinical outcomes. Although it is 
well recognized that cancer can activate the coagulation 
cascade, it is less well-known that activation of the 
coagulation system may also support tumor progression, 
and more specifically tumor angiogenesis. Additionally, 
platelet activation in cancer patients and its impact on 
tumor progression and metastasis further expand the role 
of the haemostatic system in malignancy. The problem 
of thrombosis in patients with metastatic diseases is a 
serious concern for clinicians. Warfarin and unfractionated 
heparin are effective anticoagulants which have been used 
in clinical practice for more than 50 years. However, their 
use is associated with some concerns, including the need 
for intensive coagulation monitoring, wide variation in 
dose-response relationships, multiple drug interactions 
(in the case of warfarin), and serious immune-mediated 
thrombocytopenia (in the case of heparin). The introduction 
of low-molecular-weight heparin (LMWH) improved the 
anticoagulation therapy by enhancing efficacy and 
eliminating the need for intensive coagulation monitoring. 
An important role has been demonstrated for LMWH 
(tinzaparin), warfarin, anti-factor VIIa, and recombinant 
TF pathway inhibitor in the regulation of angiogenesis, 
tumor growth and tumor metastasis(42). Fondaparinux, 
the first selective factor Xa inhibitor, represents another 
improvement in anticoagulation therapy. By binding 
rapidly and strongly to antithrombin, its sole physiologic 
target in plasma, fondaparinux catalyzes specifically the 
inhibition of factor Xa, which results in effective and linear 
dose-dependent inhibition of thrombin generation(43). 
Additionally, efficient inhibition of factor Xa activity 
impairs the activation of TF/factor VIIa complex leading to 
downregulation of procoagulant state, pro-angiogenesis, 
and proinflammatory factors induced by TF/factor VIIa(43). 
Furthermore, a number of orally active direct antithrombin 
and anti-factor Xa are in advanced clinical development 
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for various thromboembolic disorders. In the future, they 
might also be used as part of an anti-angiogenic therapy, 
to block vessel growth.
Perspectives
Undoubtedly a comprehensive compendium of 
angiogenic regulation is still to be written. Despite the 
exceptionally increasing informative data accumulated in 
recent years, and the development of new methodological 
options for molecular investigation, we still have several 
unsolved issues to be elucidated. Recent years have been 
motivating in this field especially because basic research 
is now integrated to clinical-pathological setting. New 
questions and answers are gradually emerging in the 
context of daily routine practice.
Knowledge of blood coagulation cascade players in 
angiogenesis opens a new avenue for research with a perspective 
to join anti-coagulant therapies into the armamentarium of 
anti-angiogenesis and anti-cancer strategies.
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